BACKGROUND: Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis) is challenging because commonly used second-line drugs are poorly efficacious and highly toxic. Although World Health Organization group 5 drugs are not recommended for routine use because of unclear activity, some may have untapped potential as more efficacious or better tolerated alternatives. METHODS: We conducted an exhaustive review of in vitro, animal, and clinical studies of group 5 drugs to identify critical research questions that may inform their use in current treatment of DR-tuberculosis and clinical trials of new DR-tuberculosis regimens. RESULTS: Clofazimine may contribute to new short-course DR-tuberculosis regimens. Beta-lactams merit further evaluation-specifically optimization of dose and schedule. Linezolid appears to be effective but is frequently discontinued due to toxicity. Thiacetazone is too toxic to warrant further evaluation. Mycobacterium tuberculosis has intrinsic inducible resistance to clarithromycin. CONCLUSIONS: Clofazimine and beta-lactams may have unrealized potential in the treatment of DR-tuberculosis and warrant further study. Serious toxicities or intrinsic resistance limit the utility of other group 5 drugs. For several group 5 compounds, better understanding of structure-toxicity relationships may lead to better-tolerated analogs.
BACKGROUND: Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis) is challenging because commonly used second-line drugs are poorly efficacious and highly toxic. Although World Health Organization group 5 drugs are not recommended for routine use because of unclear activity, some may have untapped potential as more efficacious or better tolerated alternatives. METHODS: We conducted an exhaustive review of in vitro, animal, and clinical studies of group 5 drugs to identify critical research questions that may inform their use in current treatment of DR-tuberculosis and clinical trials of new DR-tuberculosis regimens. RESULTS:Clofazimine may contribute to new short-course DR-tuberculosis regimens. Beta-lactams merit further evaluation-specifically optimization of dose and schedule. Linezolid appears to be effective but is frequently discontinued due to toxicity. Thiacetazone is too toxic to warrant further evaluation. Mycobacterium tuberculosis has intrinsic inducible resistance to clarithromycin. CONCLUSIONS:Clofazimine and beta-lactams may have unrealized potential in the treatment of DR-tuberculosis and warrant further study. Serious toxicities or intrinsic resistance limit the utility of other group 5 drugs. For several group 5 compounds, better understanding of structure-toxicity relationships may lead to better-tolerated analogs.
Authors: R T Mehta; A Keyhani; T J McQueen; B Rosenbaum; K V Rolston; J J Tarrand Journal: Antimicrob Agents Chemother Date: 1993-12 Impact factor: 5.191
Authors: Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Rosemary V Swanson; Nicole C Ammerman; Bongani Ngcobo; John Adamson; Chivonne Moodley; Afton Dorasamy; Sashen Moodley; Zinhle Mgaga; Linda A Bester; Sanil D Singh; Deepak V Almeida; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Jacques H Grosset; Sandeep Tyagi; Deepak V Almeida; Paul J Converse; Si-Yang Li; Nicole C Ammerman; William R Bishai; Donald Enarson; Arnaud Trébucq Journal: Am J Respir Crit Care Med Date: 2013-09-01 Impact factor: 21.405
Authors: Mikhail D Murashov; Vernon LaLone; Phillip M Rzeczycki; Rahul K Keswani; Gi S Yoon; Sudha Sud; Walajapet Rajeswaran; Scott Larsen; Kathleen A Stringer; Gus R Rosania Journal: J Invest Dermatol Date: 2017-10-16 Impact factor: 8.551
Authors: D H Vu; M S Bolhuis; R A Koster; B Greijdanus; W C M de Lange; R van Altena; J R B J Brouwers; D R A Uges; J W C Alffenaar Journal: Antimicrob Agents Chemother Date: 2012-08-27 Impact factor: 5.191
Authors: Cornel Burger; Marique Aucamp; Jan du Preez; Richard K Haynes; Andile Ngwane; Jeanetta du Plessis; Minja Gerber Journal: Pharm Res Date: 2018-08-07 Impact factor: 4.200